AdvaMed
Advanced Medical Technology Association

Industry View – Draft
Prospective Registry Objectives & Statistical Considerations

Dan Schaber PharmD
Vice President Medtronic CRDM Clinical Research

BRINGING INNOVATION TO PATIENT CARE WORLDWIDE

April 28, 2009

AdvaMed
Advanced Medical Technology Association

Background

- Specify the purpose of obtaining additional information to insure that hypothesis is appropriately formulated
  - Improve physician/patient decision making?
  - Determine if patients in registry are same as those in trial?
    - Demographics, indications….
  - Generate hypotheses for future trials?
  - Determine external validity of RCT evidence? (generalizability)
    - Determine safety in sub-populations?
  - Restrict coverage/access?
- Determine what safety we are interested in?
  - Procedural, in-hospital, near and long term safety or all?
  - What influence does concomitant drug therapy have?
  - Address key stakeholder requirements
- Acknowledge industry's longstanding expertise & initiative
  - We understand and support evidence based medicine
  - We invest in our own, & FDA mandated post market studies
  - We develop robust clinical & economic evidence for physicians, patients & payers

AdvaMed
Advanced Medical Technology Association

What a-fib ablation safety hypotheses could be appropriately answered in a national registry? Who decides?

- Describe the Procedural, in-hospital, near and long term safety
  - Safety defined as a composite of total mortality, disabling stroke, serious bleed & SCA or…
  - Potential for significant bias is great based on lack of randomization, patient factors, concomitant drug therapy…
  - Estimate the overall safety in the entire population with confidence intervals
  - Estimate the occurrence of components of the safety composite over time
- Comparison between sub groups within the registry or to historical controls has the potential for significant bias and should be viewed as a signal to be considered in hypothesis generation.
- Determining the correct objectives requires multiple stakeholder input.
- Can a single registry address the breadth of requirements?
- This will compete with FDA required post market surveillance
- Independent registries & single center experiences have shown very different results

AdvaMed
Advanced Medical Technology Association

Industry View: Prospective Registry Objectives & Statistical Considerations

- Put a multi-stakeholder board including industry together to define objectives & oversee implementation, access, integrity etc.
  - Specify the purpose of obtaining additional information to insure that hypothesis is appropriately formulated
  - Determine & define what safety we are interested in – procedural, in hospital, short or long term
  - Determine the level of precision necessary – is a census really necessary? Why won't a sample be sufficient? – tradeoff between resources necessary & value of the evidence.

AdvaMed
Advanced Medical Technology Association

How do we manage data access?
For what purposes can & should it be used?

- There should be a multi-stakeholder board that determines & oversees
  - Objectives, data to be collected, analysis, publications
  - Data integrity, security, compliance (HIPAA…)
  - Stakeholder access to data
- Participants (physicians, hospitals, manufacturers) should have access to their detailed data and all de-identified data at regular pre-defined intervals
  - HIPAA compliant …
  - Should manufacturers see each others data or just product blind data?
  - Manufacturers allowed use for research, development & regulatory & publications of data on their own products
- Publications must identify the registry as the source of the data
- Informed consent should be obtained from patients whose data is included in the registry

AdvaMed

Advanced Medical Technology Association

BRINGING INNOVATION TO PATIENT CARE WORLDWIDE

April 28, 2009